by jlohrconsulting | Aug 8, 2025 | Uncategorized
Int J Eat Disord. 2025 Aug 8. doi: 10.1002/eat.24520. Online ahead of print. ABSTRACT The good news is that Bruns and colleagues’ robust meta-analysis of randomized controlled trials (RCTs) of individual Cognitive-Behavioral Therapy (CBT) for eating disorders...
by jlohrconsulting | Aug 8, 2025 | Uncategorized
Stud Health Technol Inform. 2025 Aug 7;329:98-102. doi: 10.3233/SHTI250809. ABSTRACT Epilepsy requires accurate diagnosis through systematic classification of patients for effective treatment, targeted therapeutic interventions, and structured research for enhanced...
by jlohrconsulting | Aug 8, 2025 | Uncategorized
Front Immunol. 2025 Jul 24;16:1610486. doi: 10.3389/fimmu.2025.1610486. eCollection 2025. ABSTRACT BACKGROUND: Glial fibrillary acidic protein-immunoglobulin G (GFAP-IgG) can coexist with aquaporin-4-IgG (AQP4-IgG) or myelin oligodendrocyte glycoprotein-IgG (MOG-IgG)....
by jlohrconsulting | Aug 8, 2025 | Uncategorized
Br J Gen Pract. 2025 Aug 7:BJGP.2025.0092. doi: 10.3399/BJGP.2025.0092. Online ahead of print. ABSTRACT Background Antidepressant prescribing during pregnancy is rising but uncertainties remain surrounding safety. Evidence relating to antidepressant use during...
by jlohrconsulting | Aug 8, 2025 | Uncategorized
Sci Rep. 2025 Aug 7;15(1):28919. doi: 10.1038/s41598-025-14385-2. ABSTRACT Viloxazine and dextroamphetamine as newly approved drugs for the medical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in recent years give new options for the treating of...
Recent Comments